ePrints

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)

Lookup NU author(s): Dr David Sheridan, Dr R Neely, Professor Margaret Bassendine

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The six different HCV-genotypes have marked differences in response to therapy with pegylated interferon-α and ribavirin. The introduction of the direct acting antiviral (DAA) protease inhibitors, telaprevir and boceprevir in combination with pegylated interferon-α and ribavirin has become the new standard of care for genotype 1 infection. Several host factors associated with response to pegylated interferon-α and ribavirin are not as important in predicting response to triple therapy, and yet low-density lipoprotein cholesterol (LDLC) and statin use remain important associations of outcome with DAAs. This review focuses on the clinical associations between lipids and treatment response to interferon based antiviral treatments. We consider how understanding the interactions of HCV and host lipid metabolism remains relevant in the era of DAAs for genotype 1 infection and for treatment of non-genotype 1 chronic hepatitis C.

Publication metadata

Author(s): Sheridan DA, Neely RD, Bassendine MF

Publication type: Review

Publication status: Published

Journal: Clinics and Research in Hepatology and Gastroenterology

Year: 2013

Volume: 37

Issue: 1

Pages: 10-16

Print publication date: 01/02/2013

ISSN (print): 2210-7401

ISSN (electronic): 2210-741X

URL: http://dx.doi.org/10.1016/j.clinre.2012.07.002

DOI: 10.1016/j.clinre.2012.07.002

PubMed id: 22959093

Share